News Home

Analyst Rating: Will Navidea Biopharmaceuticals Inc (NAVB) Stock Outperform the Market?

Wednesday, February 10, 2021 11:59 AM | InvestorsObserver Analysts
Analyst Rating: Will Navidea Biopharmaceuticals Inc (NAVB) Stock Outperform the Market?

Analysts who follow Navidea Biopharmaceuticals Inc (NAVB) on average expect it to gain 166.90% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.

That average rating earns Navidea Biopharmaceuticals Inc an Analyst Ranking of 78, which means it ranks higher than 78 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating NAVB a Strong Buy today. Find out what this means to you and get the rest of the rankings on NAVB!

Why are Analyst Ratings Important?

You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.

InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.

What's Happening With Navidea Biopharmaceuticals Inc Stock Today?

Navidea Biopharmaceuticals Inc (NAVB) stock is trading at $2.81 as of 11:46 AM on Wednesday, Feb 10, a drop of -$0.09, or -3.1% from the previous closing price of $2.90. The stock has traded between $2.63 and $3.01 so far today. Volume today is 338,165 compared to average volume of 408,714.

Click Here to get the full report on Navidea Biopharmaceuticals Inc (NAVB) Stock.

You May Also Like